Helen Hobbs

Last updated
Helen Hobbs
BornMay 5, 1952
NationalityAmerican
Education Stanford University (BS) Case Western Reserve University School of Medicine (MD)
OccupationProfessor
Employer University of Texas Southwestern Medical Center

Helen Haskell Hobbs (born May 5, 1952 in Boston, Massachusetts) [1] is an American medical researcher who is professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2018 Harrington Prize for Innovation in Medicine. [2] She and Jonathan C. Cohen found that people with hypomorphic PCSK9 mutations had lower LDL-cholesterol levels and were almost immune to heart disease. This finding led to the development of a new class of cholesterol-lowering drugs that mimic the effects of the PCSK9 mutations. [3] She and Cohen also identified the first genetic risk factor for fatty liver disease, a burgeoning health problem that can lead to cirrhosis and liver cancer. Their laboratory has shown that mutation in PNPLA3 causes accumulation of PNPLA3 on lipid droplets, which compromises the mobilization of triglycerides from liver cells. She sits on the Board of Directors at Pfizer.

Contents

Education

Hobbs graduated from Stanford University and went to medical school at Case Western Reserve University School of Medicine. She completed an internship in internal medicine at Columbia-Presbyterian Medical Center, [4] where she met her future husband, a Texan who trained at UT Southwestern. [5] Together, Hobbs and her husband, Dr. Dennis Stone, moved to Dallas, Texas in 1980, where she completed her medical training at Parkland Memorial Hospital, including a one-year stint as chief resident.

Following the advice of Donald Seldin, [6] the chairman of medicine at UT Southwestern Medical Center, she chose to pursue research after residency. Again, following Dr. Seldin's recommendation, Hobbs took a research post-doctoral position studying lipoproteins at UT Southwestern in the laboratory of Michael S. Brown and Joseph L. Goldstein, Nobel Prize in Medicine winners in 1985.

Research

In 1987 Hobbs joined the faculty of UT Southwestern Medical Center where she is the Eugene McDermott Distinguished Chair for the Study of Human Growth and Development. [7] In 1999, she co-founded the Dallas Heart Study with a grant from the Donald W. Reynolds Foundation. [8] This study takes genetic samples of a representative segment of the population of Dallas County, and correlates them to the subject's health metrics. Through this study, she found that variations in the gene PCSK9 [9] led to lower plasma cholesterol and protection from cardiovascular disease. Another major focus of her career is to understand the basis of fatty liver disease. She and Jonathan Cohen have shown that variations in the DNA sequences of PNPLA3 and TM6SF2 confer susceptibility to fatty liver disease, soon to be the number one indication for liver transplantation.

Awards

YearAward [9]
2019Anitschkow Prize
2018Foundation Lefoulon-Delalande Grand prix Award
2018Harrington Prize for Innovation in Medicine
2017 Schottenstein Prize
2016 Passano Award (with Jonathan C. Cohen  [ de ])
2015 Breakthrough Prize in Life Sciences
2015 Pearl Meister Greengard Prize, Rockefeller University
2012International Atherosclerosis Society Prize
2007 American Heart Association Distinguished Scientist Award
2007 National Academy of Sciences
2006 American Academy of Arts and Sciences
2005 Heinrich Wieland Prize
2004 National Academy of Medicine
1997 Association of American Physicians
1991 American Society for Clinical Investigation

Related Research Articles

<span class="mw-page-title-main">Low-density lipoprotein</span> One of the five major groups of lipoprotein

Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein that transport all fat molecules around the body in extracellular water. These groups, from least dense to most dense, are chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL delivers fat molecules to cells. LDL is involved in atherosclerosis, a process in which it is oxidized within the walls of arteries.

The University of Texas Southwestern Medical Center is a public academic health science center in Dallas, Texas. With approximately 23,000 employees, more than 3,000 full-time faculty, and nearly 4 million outpatient visits per year, UT Southwestern is the largest medical school in the University of Texas System and the State of Texas.

<span class="mw-page-title-main">Fatty liver disease</span> Medical condition related to obesity

Fatty liver disease (FLD), also known as hepatic steatosis and steatotic liver disease (SLD), is a condition where excess fat builds up in the liver. Often there are no or few symptoms. Occasionally there may be tiredness or pain in the upper right side of the abdomen. Complications may include cirrhosis, liver cancer, and esophageal varices.

<span class="mw-page-title-main">Joseph L. Goldstein</span> American biochemist

Joseph Leonard Goldstein ForMemRS is an American biochemist. He received the Nobel Prize in Physiology or Medicine in 1985, along with fellow University of Texas Southwestern researcher, Michael Brown, for their studies regarding cholesterol. They discovered that human cells have low-density lipoprotein (LDL) receptors that remove cholesterol from the blood and that when LDL receptors are not present in sufficient numbers, individuals develop hypercholesterolemia and become at risk for cholesterol related diseases, notably coronary heart disease. Their studies led to the development of statin drugs.

The University of Texas Health Science Center at Houston (UTHealth) is a public academic health science center in Houston, Texas, United States. It was created in 1972 by The University of Texas System Board of Regents. It is located in the Texas Medical Center, the largest medical center in the world. It is composed of six schools: McGovern Medical School, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, UTHealth School of Dentistry, Cizik School of Nursing, UTHealth School of Biomedical Informatics and UTHealth School of Public Health.

Ellen S. Vitetta is the director of the Cancer Immunobiology Center at the University of Texas Southwestern Medical Center in Dallas.

<span class="mw-page-title-main">Familial hypercholesterolemia</span> Genetic disorder characterized by high cholesterol levels

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein cholesterol, in the blood and early cardiovascular diseases. The most common mutations diminish the number of functional LDL receptors in the liver or produce abnormal LDL receptors that never go to the cell surface to function properly. Since the underlying body biochemistry is slightly different in individuals with FH, their high cholesterol levels are less responsive to the kinds of cholesterol control methods which are usually more effective in people without FH. Nevertheless, treatment is usually effective.

<span class="mw-page-title-main">PCSK9</span> Mammalian protein found in humans

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. It is the 9th member of the proprotein convertase family of proteins that activate other proteins. Similar genes (orthologs) are found across many species. As with many proteins, PCSK9 is inactive when first synthesized, because a section of peptide chains blocks their activity; proprotein convertases remove that section to activate the enzyme. The PCSK9 gene also contains one of 27 loci associated with increased risk of coronary artery disease.

<span class="mw-page-title-main">Thomas C. Südhof</span> German-American biochemist

Thomas Christian Südhof, ForMemRS, is a German-American biochemist known for his study of synaptic transmission. Currently, he is a professor in the school of medicine in the department of molecular and cellular physiology, and by courtesy in neurology, and in psychiatry and behavioral sciences at Stanford University.

<span class="mw-page-title-main">Eric N. Olson</span> American molecular biologist

Eric Newell Olson is an American molecular biologist. He is professor and chair of the Department of Molecular Biology at the University of Texas Southwestern Medical Center in Dallas, where he also holds the Robert A. Welch Distinguished Chair in Science, the Annie and Willie Nelson Professorship in Stem Cell Research, and the Pogue Distinguished Chair in Research on Cardiac Birth Defects.

Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.

Kern Wildenthal is an American academic and president of the Children's Medical Center Foundation in Dallas, Texas. He also holds honorary appointments as President Emeritus and Professor of Medicine Emeritus at University of Texas Southwestern Medical Center, where he served as president from 1986 to 2008.

Evolocumab, sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.

<span class="mw-page-title-main">Anoop Misra</span> Indian endocrinologist

Anoop Misra is an Indian endocrinologist and a former honorary physician to the Prime Minister of India. He is the chairman of Fortis Centre for Diabetes, Obesity and Cholesterol (C-DOC) and heads, National Diabetes Obesity and Cholesterol Foundation (NDOC). A former Fellow of the World Health Organization at the Royal Free Hospital, UK, Misra is a recipient of the Dr. B. C. Roy Award, the highest Indian award in the medical category. The Government of India awarded him the fourth highest civilian honour of the Padma Shri, in 2007, for his contributions to Indian medicine.

Donald Wayne Seldin was an American nephrologist. He worked at University of Texas Southwestern Medical Center and served as chair of the department of medicine for 36 years.

Floyd Rector is a nephrologist and emeritus professor of medicine.

John Satterfield Fordtran is an emeritus professor of gastroenterology and past president of the American Society for Clinical Investigation.

<span class="mw-page-title-main">Fouad Bashour</span> Cardiologist and academic

Fouad Bashour, MD, PhD (1924–2003) was a noted cardiologist and Ashbel Smith professor of medicine at the University of Texas Southwestern Medical Center.

Daniel Kalman Podolsky is an American gastroenterologist and member of the National Academy of Medicine. He serves as President of the University of Texas Southwestern Medical Center. and co-chairman of Southwestern Health Resources, a collaboration between UT Southwestern and Texas Health Resources that cares for patients across North Texas and includes more than 30 hospitals, 300 clinics, and 2,600 physicians.

Kiran Musunuru is an American cardiologist who is a Professor of Medicine at the University of Pennsylvania Perelman School of Medicine. He researches the genetics and genomics of cardiovascular and metabolic diseases. Musunuru is a leading expert in the field of gene-editing.

References

  1. "Helen Haskell Hobbs, Curriculum Vitae" (PDF). U. of Texas Southwestern Medical Center at Dallas, patient care web production.
  2. "The 2018 Harrington Prize for Innovation in Medicine: Helen H. Hobbs, MD". The American Society for Clinical Investigation. March 19, 2018.
  3. "Breakthrough Prizes Give Top Scientists the Rock Star Treatment". The New York Times. November 8, 2015. Retrieved November 9, 2015.
  4. "Doctor & Faculty Profiles". UT Southwestern Medical Center. Retrieved 20 February 2016.[ permanent dead link ]
  5. Neill, Ushma S. (2015). "A conversation with Helen Hobbs". The Journal of Clinical Investigation. 125 (10): 3725–3726. doi:10.1172/JCI84086. PMC   4607136 . PMID   26426073 . Retrieved 20 February 2016.
  6. Mooney, Michael J. (17 September 2013). "The Father of Dallas Medicine". D Magazine. Retrieved 20 February 2016.
  7. Hobbs, Helen. "Helen Hobbs, M.D." UT Southwestern Faculty Profiles.
  8. "Dallas Heart Study". UT Southwestern Medical Center. Retrieved 20 February 2016.
  9. 1 2 "Helen Hobbs, M.D." Retrieved 14 August 2018.